What can angiotensin antagonists do that converting-enzyme inhibition can't: The case of post-angioplastic restenosis

Canadian Journal of Physiology and Pharmacology

Volumn 74, Issue 7, 1996, Pages 867-877

  Pham, Dung ^a   Laporte, Stéphane ^a   Pérodin, Jacqueline ^a   Bourgeois, Ronald ^a   Escher, Emanuel ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Antiproliferation; Inverse agonism; Losartan; Neointima

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; 2 [N PROPYL N [2' (1H TETRAZOL 5 YL)BIPHENYL 4 YLMETHYL]AMINO]NICOTINIC ACID; ANGIOTENSIN; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; L 163017; LOSARTAN; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; UNCLASSIFIED DRUG; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CATTLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; INTIMA; MALE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RABBIT; RAT; RESTENOSIS;

EID: 0030481019     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y96-080     Document Type: Conference Paper

References (87)

1. Allen, L.F., Lefkowitz, R.J., Caron, M.G., and Cotecchia, S. 1991. G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-adrenergic receptor enhances mitogenesis and tumorigenicity. Proc. Natl. Acad. Sci. U.S.A. 88: 11 354-11 358.
2. Anonymous. 1992. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Circulation, 86: 100-110.
3. Azuma, H., Niimi, Y., and Hamasaki, H. 1992. Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan. Br. J. Pharmacol. 106: 665-671.
4. Bailey, W.L., LaFleur, D.W., Forrester, J.S., Fagin, J.A., and Sharifi, B.G. 1994. Stimulation of rat vascular smooth muscle cell glycosaminoglycan production by angiotensin II. Atherosclerosis (Shannon, Irel.), 111: 55-64.
5. Bairati, I., Roy, L., and Meyer, F. 1992. Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty. Circulation, 85: 950-956.
6. Barinaga, M. 1994. Gene therapy for clogged arteries passes test in pigs. Science (Washington, D.C.), 265: 738.
7. Bond, R.A., Leff, P., Johnson, T.D., Milano, C.A., Rockman, H.A., McMinn, T.R., Apparsundaram, S., Hyek, M.F., Kenakin, T.P., Allen, L.F., and Lefkowitz, R.J. 1995. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature (London), 374: 272-276.
8. Bosse, R., Gerold, M., Fischli, W., Hoick, M., and Escher, E. 1990. An angiotensin with prolonged action and blood pressure-lowering properties. J. Cardiovasc. Pharmacol. 16(Suppl. 4): S50-S55.
9. 1-p-benzoylphenylalanine-angiotensin, a new photoaffinity probe for selective labeling of the type 2 angiotensin receptor. Regul. Pept. 44: 215-223.
10. Brown, E.M., Pollack, M., Seidman, C.E., Chou, Y.H., Riccardi, D., and Hebert, S.C. 1995. Calcium-ion-sensing cell-surface receptors. N. Engl. J. Med. 333: 234-240.
11. Bumpus, F.M. 1977. Mechanisms and sites of action of newer angiotensin agonists and antagonists in terms of activity and receptor. Fed. Proc. 36: 2128-2132.
12. Bumpus, F.M., and Khosla, M.C. 1975. Inhibition of the pressor and aldosterone-releasing effects of angiotensin II. Clin. Sci. Mol. Med. Suppl. 2: 15s-18s.
13. Bumpus, F.M., and Khosla, M.C. 1977. Angiotensin analogues as determinants of the physiologic role of angiotensin and its metabolites. In Hypertension: physiopathology and treatment. Edited by J. Genest, E. Koiw, and O. Kuchel. McGraw-Hill, New York. pp. 183-201.
14. Burnier, M., Waeber, B., and Brunner, H.R. 1994. The advantages of angiotensin II antagonism. J. Hypertens. Suppl. 12: S7-S15.
15. Burnier, M., Pechere-Bertschi, A., Nussberger, J., Waeber, B., and Brunner, H.R. 1995. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems. Am. J. Kidney Dis. 26: 108-115.
16. Chang, M.W., Barr, E., Seltzer, J., Jiang, Y.Q., Nabel, G.J., Nabel, E.G., Parmacek, M.S., and Leiden, J.M. 1995. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science (Washington, D.C.), 267: 518-522.
17. Chang, R.S., and Lotti, V.J. 1990. Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands. Mol. Pharmacol. 37: 347-351.
18. Chang, R.S.L., Siegl, P.K.S., Clineschmidt, B.V., Mantlo, N.B., Chakravarty, P.K., Greenlee, W.J., Patchett, A.A., and Lotti, V.J. 1992. In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. 262: 133-138.
19. Chidiac, P., Hebert, T.E., Valiquette, M., Dennis, M., and Bouvier, M. 1994. Inverse agonist activity of beta-adrenergic antagonists. Mol. Pharmacol. 45: 490-499.
20. Chiu, A.T., Herblin, W.F., McCall, D.E., Ardecky, R.J., Carini, D.J., Duncia, J.V., Pease, L.J., Wong, P.C., Wexler, R.R., Johnson, A.L., and Timmermans, P.B.M.W.M. 1989. Identification of angiotensin II receptor subtypes. Biochem. Biophys. Res. Commun. 165: 196-203.
21. Christen, Y., Waeber, B., Nussberger, J., Porchet, M., Borland, R.M., Lee, R.J., Maggon, K., Shum, L., Timmermans, P.B., and Brunner, H.R. 1991. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation, 83: 1333-1342.
22. Cody, R.J. 1994. The clinical potential of renin inhibitors and angiotensin antagonists. Drugs, 47: 586-598.
23. Criscione, L., De Gasparo, M., Buhlmayer, P., Whitebread, S., Ramjoue, H.P., and Wood, J. 1993. Pharmacological profile of Valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br. J. Pharmacol. 110: 761-771.
24. Croog, S.H., Levine, S., Testa, M.A., Brown, B., Bulpitt, C.J., Jenkins, C.D., Klerman, G.L., and Williams, G.H. 1986. The effects of antihypertensive therapy on the quality of life. N. Engl. J. Med. 314: 1657-1664.
25. De Gasparo, M., Levens, N.R., Kamber, B., Furet, P., Whitebread, S., Breckler, S., and Bottari, S. 1994. The angiotensin II AT2 receptor subtype. In Angiotensin receptors. Edited by J.M. Saavedra and P.B.M.W.M. Timmermans. Plenum Press, New York. pp. 95-117.
26. De Laszlo, S.E., Quagliato, C.S., Greenlee, W.J., Patchett, A.A., Chang, R.S., Lotti, V.J., Chen, T.B., Scheck, S.A., Faust, K.A., Kivlighn, S.S., et al. 1993. A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor. J. Med. Chem. 36: 3207-3210.
27. Dudley, D.T., Parck, R.L., Major, T.C., Lu, G.H., Brums, R.F., Klinkefur, B.A., Hodges, J.C., and Weishaar, R.E. 1990. Subclasses of angiotensin II binding sites and their functional significance. Mol. Pharmacol. 38: 370-377.
28. Duncia, J.V., Chiu, A.T., Carini, D.J., Gregory, G.B., Johnson, A.L., Price, W.A., Wells, G.J., Wong, P.C., Calabrese, J.C., and Timmermans, P.B. 1990. The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J. Med. Chem. 33: 1312-1329.
29. Escher, E., Nguyen, T.M., and Regoli, D. 1978. Photoaffinity labeling of the angiotensin II receptor; pharmacology of the labeling peptides in the dark. Can. J. Physiol. Pharmacol. 56: 956-962.
30. Fraker, P.J., and Speck, J.C., Jr. 1978. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem. Biophys. Res. Commun. 80: 849-857.
31. Furchgott, R.F., and Bhadrakom, S. 1953. Reactions of strips of rabbit aorta to epinephrine, isopropylarterenol, sodium nitrite and other drugs. J. Pharmacol. Exp. Ther. 108: 129-143.
32. Glossmann, H., Baukal, A.J., and Catt, K.J. 1974. Properties of angiotensin II receptors in the bovine and rat adrenal cortex. J. Biol. Chem. 249: 825-834.
33. Goedeweeck, R., and De Schryver, F.C. 1984. Solvent effects on intramolecular excimer formation in n-acetyl-bis(pyrenylalanine)-methylester. Photochem. Photobiol. 39: 515-520.
34. Goghari, M.H., Franklin, K.J., and Moore, G.J. 1986. Structure-activity relationships for the competitive angiotensin antagonists [sarcosine,O-methyltyrosine4]angiotensin II (sarmesin). J. Med. Chem. 29: 1121-1124.
35. Gradman, A.H., Arcuri, K.E., Goldberg, A.I., Ikeda, L.S., Nelson, E.B., Snavely, D.B., and Sweet, C.S. 1995. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension (Dallas), 25: 1345-1350.
36. Griendling, K.K., Lassegue, B., Murphy, T.J., and Alexander, R.W. 1994. Angiotensin II receptor pharmacology. Adv. Pharmacol. 28: 269-306.
37. Gruntzig, A. 1978. Transluminal dilatation of coronary-artery stenosis. Lancet, 1: 263.
38. Hermans, W.R., Foley, D.P., Rensing, B.J., and Serruys, P.W. 1994. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographie analysis in 778 lesions - further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis). Am. Heart J. 127: 483-494.
39. Holck, M., Bosse, R., Fischli, W., Gerold, H., and Escher, E. 1989. An angiotensin II antagonist with strongly prolonged action. Biochem. Biophys. Res. Commun. 160: 1350-1356.
40. Hsieh, K.H., LaHann, T.R., and Speth, R.C. 1989. Topographic probes of angiotensin and receptor: potent angiotensin II agonist containing diphenylalanine and long-acting antagonists containing biphenylalanine and 2-indan amino acid in position 8. J. Med. Chem. 32: 898-903.
41. Janiak, P., Pillon, A., Prost, J.F., and Vilaine, J.P. 1992. Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension (Dallas), 20: 737-745.
42. Johnson, R.G. 1994. The effects of antithrombotics and angiotensin receptor antagonists in a porcine coronary artery restenosis model. In IBC's International Conference on Restenosis, Cambridge, Mass., Oct. 28, 1994. Edited by International Business Communications. Southborough, Mass.
43. Kalenga, M.K., De Gasparo, M., Thomas, K., and De Hertogh, R. 1995. Angiotensin II stimulates estradiol secretion from human placental explants through AT1 receptor activation. J. Clin. Endocrinol. Metab. 80: 1233-1237.
44. Kambayashi, Y., Bardhan, S., Takahashi, K., Tsuzuki, S., Inui, H., Hamakubo, T., and Inagami, T. 1993. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. 268: 24 543 - 24 546.
45. Kjelsberg, M.A., Cotecchia, S., Ostrowski, J., Caron, M.G., and Lefkowitz, R.J. 1992. Constitutive activation of the alpha IB-adrenergic receptor by all amino acid substitutions at a single site. Evidence fora region which constrains receptor activation. J. Biol. Chem. 267: 1430-1433.
46. Landau, C., Lange, R.A., and Hillis, L.D. 1994. Percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 330: 981-993.
47. Laporte, S., and Escher, E. 1992. Neointima formation after vascular injury is angiotensin II mediated. Biochem. Biophys. Res. Commun. 187: 1510-1516.
48. Laporte, S., Gervais, A., and Escher, E. 1991. Angiotensin II antagonists prevent the myoproliferative response after vascular injury. FASEB J. 5: A869.
49. 3) phenylalanine. Helv. Chim. Acta, 66: 960-970.
50. Leeb-Lundberg, L.M., Mathis, S.A., and Herzig, M.C. 1994. Antagonists of bradykinin that stabilize a G-protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells. J. Biol. Chem. 269: 25 970-25 973.
51. Lefkowitz, R.J. 1993. G-protein-coupled receptors. Turned on to ill effect. Nature (London), 365: 603-604.
52. Luo, X., Zhang, D., and Weinstein, H. 1994. Ligand-induced domain motion in the activation mechanism of a G-protein-coupled receptor. Protein Eng. 7: 1441-1448.
53. Macari, D., Bottari, S., Whitebread, S., De Gasparo, M., and Levens, N. 1993. Renal actions of the selective angiotensin AT2 receptor ligands CGP 42112B and PD 123319 in the sodium-depleted rat. Eur. J. Pharmacol. 249: 85-93.
54. Marrero, M.B., Schieffer, B., Paxton, W.G., Heerdt, L., Berk, B.C., Delafontaine, P., and Bernstein, K.E. 1995. Direct stimulation of Jak/STAT pathway by the angiotensin II AT, receptor. Nature (London), 375: 247-250.
55. McGarry, T.F., Jr., Gottlieb, R.S., Morganroth, J., Zelenkofske, S.L., Kasparian, H., Duca, P.R., Lester, R.M., and Kreulen, T.H. 1992. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am. Heart J. 123: 1445-1451.
56. Mukoyama, M., Nakajima, M., Horiuchi, M., Sasamura, H., Pratt, R.E., and Dzau, V.J. 1993. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. 268: 24 539-24 542.
57. Murphy, T.J., Alexander, R.W., Griendling, K.K., Runge, M.S., and Bernstein, K.E. 1991. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature (London), 351: 233-236.
58. Ohno, T., Gordon, D., San, H., Pompili, V.J., Imperiale, M.J., Nabel, G.J., and Nabel, E.G. 1994. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science (Washington, D.C.), 265: 781-784.
59. Osterrieder, W., Muller, R.K., Powell, J.S., Clozel, J.P., Hefti, F., and Baumgartner, H.R. 1991. Role of angiotensin II in injury-induced neointima formation in rats. Hypertension (Dallas), 18(4 Suppl.): 1160-1164.
60. Pals, D.T., Denning, G.S., and Keenan, R.E. 1979. Historical development of saralasin. Kidney Int. Suppl. 9: S7-S10.
61. Park, W.K., Smeby, R.R., and Bumpus, P.M. 1967. Synthesis of [5-isoleucine, 8-alanine]angiotensin II by the solution method synthesis and the solid-phase method synthesis. Biochemistry, 6: 3458-3464.
62. Powell, J.S., Clozel, J.-P., Muller, R.K., Kuhn, H., Hefti, F., Hosang, M., and Baumgartner, H.R. 1989. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science (Washington, D.C.), 245: 186-188.
63. Rakugi, H., Kim, D.K., Krieger, J.E., Wang, D.S., Dzau, V.J., and Pratt, R.E. 1994. Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J. Clin. Invest. 93: 339-346.
64. Rao, G.N., Griendling, K.K., Frederickson, R.M., Sonenberg, N., and Alexander, R.W. 1994. Angiotensin II induces phosphorylation of eukaryotic protein synthesis initiation factor 4E in vascular smooth muscle cells. J. Biol. Chem. 269: 7180-7184.
65. Samanen, J., Narindray, D., Adams, W., Jr., Cash, T., Yellin, T., and Regoli, D. 1988. Effects of D-amino acid substitution on antagonist activities of angiotensin II analogues. J. Med. Chem. 31: 510-516.
66. Sasaki, K., Yamano, Y., Bardhan, S., Iwai, N., Murray, J.J., Hasegawa, M., Matsuda, Y., and Inagami, T. 1991. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature (London), 351: 230-233.
67. Schipani, E., Kruse, K., and Juppner, H. 1995. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science (Washington, D.C.), 268: 98-100.
68. Schutz, W., and Freissmuth, M. 1992. Reverse intrinsic activity of antagonists on G protein coupled receptors. Trends Pharmacol. Sci. 13: 376-380.
69. Seidel, R., Scharf, B., Gautel, M., Kleine, K., Oesterhelt, D., and Engelhard, M. 1995. The primary structure of sensory rhodopsin II: a member of an additional retinal protein subgroup is coexpressed with its transducer, the halobacterial transducer of rhodopsin II. Proc. Natl. Acad. Sci. U.S.A. 92: 3036-3040.
70. Shenker, A., Laue, L., Kosugi, S., Merendino, J.J., Jr., Minegishi, T., and Cutler, G.B., Jr. 1993. A constitutively activating mutation of the lutemizing hormone receptor in familial male precocious puberty. Nature (London), 365: 652-654.
71. Simons, M., Edelman, E.R., DeKeyser, J.-L., Langer, R., and Rosenberg, R.D. 1992. Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature (London), 359: 67-70.
72. Solomon, T.A., and Buckley, J.P. 1974. Inhibitory effects of central hypertensive activity of angiotensin I and II by 1-sar-8-alaangiotensin II (saralasin acetate). J. Pharm. Sci. 63: 1109-1113.
73. Stoll, M., Steckelings, U.M., Paul, M., Bottari, S.P., Metzger, R., and Unger, T. 1995. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J. Clin. Invest. 95: 651-657.
74. Streeten, D.H., Freiberg, J.M., Anderson, G.H., and Dalakos, T.G. 1975. Identification of angiotensinogenic hypertension in man using 1-sar-8-ala-angiotensin II (Saralasin, P-113). Circ. Res. 36(6 Suppl. 1): 125-132.
75. Sung, C.P., Arleth, A.J., Storer, B.L., and Ohlstein, E.H. 1994. Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J.Pharmacol. Exp. Ther. 271: 429-437.
76. Taguchi, J., Abe, J., Okazaki, H., Ochiai, M., Ohno, M., Takuwa, Y., and Kurokawa, K. 1993. Angiotensin converting enzyme inhibitors or DuP 753 prevent neointimal formation following balloon injury with single topical or multiple systemic application. Biochem. Biophys. Res. Commun. 196: 969-974.
77. Tanguay, J.F., Zidar, J.P., Phillips, H.R., 3rd, and Stack, R.S. 1994. Current status of biodegradable stents. Cardiol.Clin. 12: 699-713.
78. Topol, E.J., Ellis, S.G., Cosgrove, D.M., Bates, E.R., Muller, D.W.M., Schork, N.J., Schork, M.A., and Loop, F.D. 1993. Analysis of coronary angioplasty practice in the United States with an insurance-claims database. Circulation, 87: 1489-1497.
79. Trumpp-Kallmeyer, S., Hoflack, J., Bruinvels, A., and Hibert, M. 1992. Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. J. Med. Chem. 35: 3448-3462.
80. Unwin, N. 1995. Acetylcholine receptor channel imaged in the open state. Nature (London), 373: 37-43.
81. 1 receptors in neointima of rat carotid artery and aorta after balloon catheter injury. Peptides, 15: 1205-1212.
82. Weber, H., Taylor, D.S., and Molloy, C.J. 1994. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin. J. Clin. Invest. 93: 788-798.
83. Whitebread, S., Mele, M., Kamber, B., and De Gasparo, M. 1989. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem. Biophys. Res. Commun. 163: 284-291.
84. Wilensky, R.L., March, K.L., and Hathaway, D.R. 1991. Direct intraarterial wall injection of microparticles via a catheter: a potential drug delivery strategy following angioplasty. Am. Heart J. 122(4 Part 1): 1136-1140.
85. Wong, P.C., Price, W.A., Chiu, A.T., Duncia, J.V., Carini, D.J., Wexler, R.R., Johnson, A.L., and Timmermans, P.B. 1990. Nonpeptide angiotensin II receptor antagonists. 11. Pharmacology of EXP3174- an active metabolite of DuP 753, an orally active anti-hypertensive agent. J. Pharmacol. Exp. Ther. 255: 211-217.
86. 1). J. Biol. Chem. 270: 14024-14030.
87. Zydowsky, T.M., Opgenorth, T.J., Kerkman, D.J., and Debernardis, J.F. 1994. Characterization of antihypertensive activity of ABBOTT-81988, a nonpeptide angiotensin II antagonist in the renal hypertensive rat. J. Pharmacol. Exp. Ther. 268: 427-433.